PITTSBURGH, June 30 /PRNewswire/ -- Cellumen, Inc., the Cellular
Systems Biology Company, announced today the initiation of a research
collaboration with the National Center for Toxicology Research (NCTR), a
research center of the Food and Drug Administration (FDA). Under the
agreement, Cellumen will use its proprietary CellCiphr(R) toxicity risk
assessment technology to profile blinded samples of known liver toxicity
compounds including both failed and marketed drugs for the NCTR. The NCTR
will incorporate the knowledge generated by Cellumen to develop a liver
toxicity knowledge base. Cellumen will use the profiling data and compound
safety data from the collaboration to further develop the diversity in the
CellCiphr database and the types of cell panels, as well as to advance the
classifier informatics tools.
"Failure to predict human toxicity among drug candidates early in the
discovery/development process is a leading challenge for the pharmaceutical
industry," stated D. Lansing Taylor, Ph.D., CEO of Cellumen. "Patients
demand and deserve safe and effective drugs, while pharmaceutical companies
are increasingly challenged to profitably meet that demand. Cellumen's
vision is working toward the goal of replacing animal testing with a human
in vitro system in order to facilitate the development of safer, more
effective drugs," added Dr. Taylor.
By applying CellCiphr toxicity profiling early in the discovery and
lead optimization phases, drug companies will accurately identify compounds
with high human toxic liabilities. Actions can be taken to either
de-prioritize high-risk compounds, or remove high-risk compounds from a
lead series that ultimately would prove to be toxic. Cellumen is at the
forefront of drug safety profiling services to aid in predicting drug
toxicity early in the discovery/development process.
About Cellumen:
Cellumen is the leading innovator in cellular systems biology (CSB(TM))
solutions providing the most accurate predictions of drug efficacy and
safety, thus reducing failure rates and cutting development costs.
Cellumen's CSB solutions are driving "Discovery Toxicology" by addressing
the full complexity of disease and safety. Leading global organizations
such as the Mayo Clinic, Hamamatsu Photonics K.K., the EPA, NIH and top
pharmaceutical companies partner with Cellumen.
About CellCiphr(R):
CellCiphr is the only cell-based assay solution combining
tissue-specific cells, multiplexed functional biomarkers, advanced
classifiers, and a compound reference library in order to allow drug
developers to accurately identify drug candidates that have high efficacy
and low toxicity. CellCiphr is capable of analyzing greater than 10
functional biomarkers per assay that are used as sentinels for analysis of
mechanism of action and toxicity of new compounds applied to both rodent
and human cells.
See Also:
- Diabetes Information and Tips
- LifeSecure Insurance Company Names New Vice President of Sales
- Raptor Pharmaceuticals Closes $10 Million Private Placement
- Cardiac Science Announces Inclusion in Russell 3000 Index
- The Greatest Reason In The World For Fat Removal
[Via Healthcare]
0 коментарі:
Post a Comment